Chapter 23: Q15P (page 829)
Is trimethoprim a mechanism-based inhibitor of bacterial dihydrofolate reductase?
Short Answer
Trimethoprim is not a mechanism-based inhibitor of bacterial DHFR because it is a reversible inhibitor.
Chapter 23: Q15P (page 829)
Is trimethoprim a mechanism-based inhibitor of bacterial dihydrofolate reductase?
Trimethoprim is not a mechanism-based inhibitor of bacterial DHFR because it is a reversible inhibitor.
All the tools & learning materials you need for study success - in one app.
Get started for freeWhy is dATP toxic to mammalian cells?
6-Mercaptopurine (Box 23-2), after its conversion to the corresponding nucleotide through salvage reactions, is a potent competitive inhibitor of IMP in the pathways for AMP and GMP biosynthesis. It is therefore a clinically useful anticancer agent. The chemotherapeutic effectiveness of 6-mercaptopurine is enhanced when it is administered with allopurinol. Explain the mechanism of this enhancement.
Compare the pathways of purine and pyrimidine nucleotide synthesis with respect to (a) precursors, (b) energy cost, (c) acquisition of the ribose moiety, and (d) number of enzymatic steps.
What is the role of NADPH in the formation of thymidylate?
List the starting materials and cofactors required for IMP biosynthesis.
What do you think about this solution?
We value your feedback to improve our textbook solutions.